ONCR Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 gruod. 2023 @ 21:55):

Stats
Šios dienos apimtis	135 947
Vidutinė apimtis	108 675
Rinkos kapitalizacija	3.29M
EPS	$0 ( 2024-03-21 )
Kita pelno data	( $0 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0362
ATR14	$0.00400 (3.17%)

Insider Trading

Date	Person	Action	Amount	type
2023-06-06	Shea Brian J.	Sell	0	Common Stock
2023-06-06	Shea Brian J.	Sell	15 000	Employee Stock Option (right to buy)
2023-06-06	Shea Brian J.	Sell	3 744	Employee Stock Option (right to buy)
2023-06-06	Shea Brian J.	Sell	14 700	Employee Stock Option (right to buy)
2023-06-06	Shea Brian J.	Sell	19 100	Employee Stock Option (right to buy)

INSIDER POWER
-41.90
Last 97 transactions
Buy: 2 441 000 \| Sell: 694 654

Tūris Koreliacija

Ilgas: 0.41 (neutral)

Trumpas: 0.27 (neutral)

Signal:(89.911) Neutral

Oncorus, Inc. Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Oncorus, Inc. Koreliacija - Valiuta/Žaliavos

-0.01
( neutral )

0.03
( neutral )

0.00
( neutral )

0.06
( neutral )

-0.69
( moderate negative )

-0.07
( neutral )

Oncorus, Inc. Finansinės ataskaitos

Annual	2022
Pajamos:	$0
Bruto pelnas:	$0 (0.00 %)
EPS:	$-3.02

FY	2022
Pajamos:	$0
Bruto pelnas:	$0 (0.00 %)
EPS:	$-3.02

FY	2021
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-2.56

FY	2020
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-9.35

Financial Reports:

No articles found.

Oncorus, Inc.

Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers. It is also developing ONCR-GBM, a preclinical stage oHSV program for treating brain cancer through intratumoral injection; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. The company has a clinical trial collaboration and supply agreement with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 combined with Merck's cancer immunotherapy KEYTRUDA in its Phase 1 clinical trial in patients with solid tumors. Oncorus, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.